Numis Securities Ltd Reaffirms Add Rating on Smith & Nephew (SN)
Smith & Nephew (LON: SN)‘s stock had its “add” rating restated by equities researchers at Numis Securities Ltd in a report issued on Tuesday. They currently have a $12.29 (762 GBX) target price on the stock.
Shares of Smith & Nephew opened at 689.50 on Tuesday. Smith & Nephew has a 52 week low of GBX 515.00 and a 52 week high of GBX 726.50. The company’s market cap is £6.164 billion.
A number of other firms have also recently commented on SN. Analysts at Sanford C. Bernstein reiterated a “market perform” rating on shares of Smith & Nephew in a research note to investors on Wednesday, September 26th. They now have a $11.13 price target on the stock. Finally, analysts at Nomura reiterated a “neutral” rating on shares of Smith & Nephew in a research note to investors on Wednesday, September 5th. They now have a $9.46 price target on the stock.
Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (which includes arthroscopic procedures referred to as sports medicine) and advanced wound management.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.